PROTAC ERRα ligand 1 is primarily utilized in targeted protein degradation studies, specifically focusing on the estrogen-related receptor alpha (ERRα). This compound is a key component in the development of Proteolysis-Targeting Chimeras (PROTACs), which are designed to selectively degrade ERRα, a nuclear receptor involved in various cellular processes. By leveraging the ubiquitin-proteasome system, PROTAC ERRα ligand 1 facilitates the removal of ERRα from cells, offering a powerful tool for investigating its role in diseases such as cancer, metabolic disorders, and neurodegenerative conditions. Its application is particularly valuable in preclinical research, where it aids in understanding ERRα's biological functions and validating it as a therapeutic target. Additionally, this ligand contributes to the development of novel therapeutic strategies aimed at modulating ERRα activity in pathological states.